Inventiva added three executives to its C-suite as the French biotech prepares for a Phase III readout in 4Q26 for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH). Axel-Sven Malkomes, formerly CFO of CureVac, will succeed Jean Volatier as CFO, with Volatier shifting to EVP finance and corporate social responsibility. The company also appointed Susan Coles as chief legal officer and Pamela Herbster as chief people officer, replacing Nathalie Harroy, who has moved into a new role. The changes underscore governance and operational preparation as Inventiva approaches its late-stage milestone.